Caption Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.01M | Sell |
70,000
-139,500
| -67% | -$7.64M | 0.02% | 650 |
|
|
2026
Q1 | $11.8M | Buy |
+209,500
| New | +$12.2M | 0.07% | 292 |
|
|
2025
Q3 | – | Sell |
-12,000
| Closed | -$660K | – | 1681 |
|
|
2025
Q2 | $660K | Sell |
12,000
-31,500
| -72% | -$1.85M | 0.01% | 1044 |
|
|
2025
Q1 | $3.08M | Buy |
43,500
+13,500
| +45% | +$908K | 0.03% | 540 |
|
|
2024
Q4 | $1.97M | Sell |
30,000
-12,500
| -29% | -$837K | 0.02% | 696 |
|
|
2024
Q3 | $2.99M | Hold |
42,500
| – | – | 0.05% | 444 |
|
|
2024
Q2 | $3.5M | Sell |
42,500
-15,000
| -26% | -$1.25M | 0.05% | 363 |
|
|
2024
Q1 | $5.02M | Buy |
57,500
+5,500
| +11% | +$492K | 0.08% | 296 |
|
|
2023
Q4 | $5.01M | Buy |
52,000
+12,600
| +32% | +$1.11M | 0.07% | 339 |
|
|
2023
Q3 | $3.49M | Sell |
39,400
-320,900
| -89% | -$28.6M | 0.05% | 424 |
|
|
2023
Q2 | $31.2M | Buy |
360,300
+280,900
| +354% | +$26.4M | 0.55% | 24 |
|
|
2023
Q1 | $7.72M | Sell |
79,400
-98,600
| -55% | -$10.2M | 0.15% | 159 |
|
|
2022
Q4 | $18.4M | Buy |
178,000
+78,000
| +78% | +$7.32M | 0.29% | 77 |
|
|
2022
Q3 | $8.48M | Sell |
100,000
-6,300
| -6% | -$561K | 0.12% | 205 |
|
|
2022
Q2 | $8.81M | Buy |
106,300
+18,800
| +21% | +$1.5M | 0.12% | 215 |
|
|
2022
Q1 | $6.74M | Buy |
87,500
+45,000
| +106% | +$3.77M | 0.08% | 331 |
|
|
2021
Q4 | $3.75M | Buy |
+42,500
| New | +$3.51M | 0.04% | 551 |
|
|
2021
Q2 | – | Sell |
-121,400
| Closed | -$9.17M | – | 1309 |
|
|
2021
Q1 | $9.17M | Sell |
121,400
-203,000
| -63% | -$16.6M | 0.2% | 127 |
|
|
2020
Q4 | $28.4M | Buy |
324,400
+144,400
| +80% | +$11.4M | 0.65% | 22 |
|
|
2020
Q3 | $13.7M | Buy |
180,000
+115,000
| +177% | +$11.6M | 0.32% | 65 |
|
|
2020
Q2 | $8.02M | Buy |
65,000
+35,000
| +117% | +$3.48M | 0.27% | 93 |
|
|
2020
Q1 | $2.53M | Sell |
30,000
-311,500
| -91% | -$26.8M | 0.14% | 197 |
|
|
2019
Q4 | $28.9M | Buy |
+341,500
| New | +$25.8M | 0.97% | 10 |
|
|
2019
Q3 | – | Sell |
-37,300
| Closed | -$3.19M | – | 715 |
|
|
2019
Q2 | $3.19M | Buy |
37,300
+23,800
| +176% | +$2.04M | 0.16% | 183 |
|
|
2019
Q1 | $1.2M | Buy |
+13,500
| New | +$1.25M | 0.07% | 315 |
|
|
2018
Q1 | – | Sell |
-40,000
| Closed | -$3.57M | – | 227 |
|
|
2017
Q4 | $3.57M | Buy |
+40,000
| New | +$3.48M | 0.37% | 82 |
|
Other funds holding BMRN
Caption Management's BMRN Position: Q2 2026 in Review
Caption Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 61% in Q2 2026, selling an estimated $1.86M and leaving 21,400 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #1061.
Caption Management first reported a position in BMRN in Q4 2017 and has held it in 18 quarters since. The position peaked at $9.9M in Q2 2023. 568 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Caption Management held 21,400 shares of BioMarin Pharmaceuticals worth $1.22M as of Q2 2026.
- Caption Management sold 33,900 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.86M.
- BioMarin Pharmaceuticals made up 0.01% of Caption Management's portfolio in Q2 2026, its #1061 holding.
- Caption Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
- Caption Management's BioMarin Pharmaceuticals position peaked at $9.9M in Q2 2023.
- 568 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.